supported by the National Natural Science Foundation of China(30672450);the National Basic Research Development Program(973Program)of China(2011CB707500)
There is no effective drug to treat Alzheimer's disease (AD), a neurodegenerative disease affecting an estimated 30 million people around the world. Strongly supported by preclinical and clinical studies, amyloid-b...
supported by grants from the National Basic Research Development program (973 Program) of China (2011CB707500);the National Natural Science Foundation of China (81173037 and 30672450);the Scientific program of Department of Science and Technology, Guangdong Province, China(2010B030700018)
Objective To model glucocorticoid-induced cognitive impairment and evaluate the neuroprotection by schi-zandrin (Sch) against dexamethasone (Dex)-induced neurotoxicity in vivo and in vitro. Methods Cerebral cortic...
supported by grants from the National Natural Science Foundation of China (30672450);the National Basic Research Development Program (973 Program) of China (2011CB707500);the Third Stage Construction Funds of National "Project 211", Department of Education, China (2005–2010)
Objective Neuronal loss in the central nervous system is central to the occurrence of neurodegenerative diseases. Pharmaceutical companies have devoted much effort to developing new drugs against such diseases, since ...
supported by National Natural Science Foundation of China(No.30672450)
β-Amyloid (Aβ) over-expression and tau hyperphosphorylation are considered to be the central events in the pathogenesis of Alzheimer's disease (AD).Studies on them may help elucidate the precise molecular patho...